These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22123916)

  • 1. Merck pays $1bn penalty in relation to promotion of rofecoxib.
    Tanne JH
    BMJ; 2011 Nov; 343():d7702. PubMed ID: 22123916
    [No Abstract]   [Full Text] [Related]  

  • 2. Merck to pay $5bn in rofecoxib claims.
    Charatan F
    BMJ; 2007 Nov; 335(7628):1011. PubMed ID: 18006982
    [No Abstract]   [Full Text] [Related]  

  • 3. A bitter pill for one Merck critic.
    McLean B
    Fortune; 2004 Dec; 150(12):58. PubMed ID: 15617422
    [No Abstract]   [Full Text] [Related]  

  • 4. Physician, divest thyself.
    Levin PJ; McGee G
    Am J Bioeth; 2006; 6(2):1-2. PubMed ID: 16500836
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation.
    Benko LB
    Mod Healthc; 2006 Apr; 36(15):16. PubMed ID: 16669517
    [No Abstract]   [Full Text] [Related]  

  • 6. Vioxx may go back on sale after scraping past FDA panel.
    Wadman M
    Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
    [No Abstract]   [Full Text] [Related]  

  • 7. Make or break time in Vioxx drama.
    Nature; 2006 Mar; 440(7082):277. PubMed ID: 16541045
    [No Abstract]   [Full Text] [Related]  

  • 8. Merck disguised "marketing publication" as medical journal to help promote Vioxx, court hears.
    Moynihan R
    BMJ; 2009 Apr; 338():b1714. PubMed ID: 19401326
    [No Abstract]   [Full Text] [Related]  

  • 9. Merck defends Vioxx in court, as publisher apologises for fake journal.
    Moynihan R
    BMJ; 2009 May; 338():b1914. PubMed ID: 19433504
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cyclooxygenase inhibitors: a never ending story?].
    Macrì R; Manfredi C
    G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
    [No Abstract]   [Full Text] [Related]  

  • 11. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
    Rahme E; Hunsche E; Toubouti Y; Chabot I
    Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AstraZeneca pays $520m fine for off label marketing.
    Tanne JH
    BMJ; 2010 Apr; 340():c2380. PubMed ID: 20430836
    [No Abstract]   [Full Text] [Related]  

  • 13. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine.
    Kmietowicz Z
    BMJ; 2009 Jan; 338():b217. PubMed ID: 19155260
    [No Abstract]   [Full Text] [Related]  

  • 14. Merck appeals rofecoxib verdict.
    Tanne JH
    BMJ; 2007 Mar; 334(7594):607. PubMed ID: 17379897
    [No Abstract]   [Full Text] [Related]  

  • 15. Serono pays $44m to settle promotion of multiple sclerosis drug.
    Tanne JH
    BMJ; 2011 May; 342():d2922. PubMed ID: 21558361
    [No Abstract]   [Full Text] [Related]  

  • 16. Merck opts for shake-up to clear drug pipeline.
    Nature; 2005 Dec; 438(7071):1076-7. PubMed ID: 16371975
    [No Abstract]   [Full Text] [Related]  

  • 17. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA warns Merck over its promotion of rofecoxib.
    Josefson D
    BMJ; 2001 Oct; 323(7316):767. PubMed ID: 11588068
    [No Abstract]   [Full Text] [Related]  

  • 19. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

  • 20. Merck faces ongoing claims after Texan ruling on rofecoxib.
    Tanne JH
    BMJ; 2005 Sep; 331(7515):471. PubMed ID: 16141139
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.